tfllr nh2(tfa)

NH2-C2-NH-Boc (PROTAC Linker 22) 是一种属于 alkyl chain 类的 PROTAC linker，可用于 PROTAC 分子的合成。

NH2-C5-NH-Boc (PROTAC Linker 23) 是一种属于 alkyl chain 类的 PROTAC linker，可用于 PROTAC 分子的合成。

NH2-C4-NH-Boc 是一种属于 Alkyl ether 类的 PROTAC linker，可用于一系列 PROTAC 分子的合成。

NH2-C6-NH-Boc 是一种属于 alkyl ether 类的 PROTAC linker ，是基于 PROTAC 技术的 Mcl-1 抑制剂。

Thalidomide-NH-PEG1-NH2 hydrochloride (4-[(2-(2-Aminoethoxy)ethyl)amino]-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione HCl) 包含基于 Thalidomide 的 cereblon 配体和 1 个 linker，是合成的 E3 连接酶配体-linker 偶联物，可用于 PROTAC 的合成。

Boc-NH-PEG7-NH2 是一种基于 PEG 的 PROTAC linker。

Thalidomide-NH-C6-NH2 hydrochloride 包含基于 Thalidomide 的 cereblon 配体和 1 个 linker，是合成的 E3 连接酶配体-linker 偶联物，可用于 PROTAC 的合成。

Thalidomide-O-amido-C6-NH2 TFA (Cereblon Ligand-Linker Conjugates 11 TFA) 包含基于 Thalidomide 的 cereblon 配体和 1 个 linker，是一种合成的 E3 连接酶配体-linker 偶联物。可用于 PROTAC 的合成分子。

Boc-NH-PEG12-NH2 (NHBoc-PEG12-amine) 是一种属于 PEG 类的 PROTAC linker，可用于 PROTAC 分子的合成。

Thalidomide-O-amido-PEG3-C2-NH2 TFA (Cereblon Ligand-Linker Conjugates 3 (TFA)) 包含基于 Thalidomide 的 cereblon 配体和 3 个单元的 PEG linker，是一种合成的 E3 连接酶配体-linker 偶联物。

Thalidomide-O-amido-PEG2-C2-NH2 TFA (E3 Ligase Ligand-Linker Conjugates 24 TFA) 包含基于 Thalidomide 的 cereblon 配体和 2 个单元的 PEG linker，是一种合成的 E3 连接酶配体-linker 偶联物。

Boc-NH-PEG11-NH2 是一种属于 PEG 类的 PROTAC linker，可用于 PROTAC 分子的合成。

Thalidomide-O-amido-C4-NH2 TFA (E3 ligase Ligand-Linker Conjugates 19 TFA) 包含基于 Thalidomide 的 cereblon 配体和 1 个 linker，是一种合成的 E3 连接酶配体-linker 偶联物。

Boc-NH-C12-NH2 是一种属于 alkyl ether 类的 PROTAC linker，可用于 PROTAC 分子的合成。

Thalidomide-O-amido-C3-NH2 TFA (Cereblon Ligand-Linker Conjugates 16 TFA) 包含基于 Thalidomide 的 cereblon 配体和 1 个 linker，是一种合成的 E3 连接酶配体-linker 偶联物，。

PROTACPTPN2 degrader-2（例187B）TFA 作为PTPN2降解剂，展现出对癌症及代谢性疾病研究的潜在效用。

Thalidomide-O-amido-PEG3-C2-NH2 TFA, a synthesized E3 ligase ligand-linker conjugate, combines the cereblon ligand based on Thalidomide and a 2-unit PEG linker for use in PROTAC technology[1].

NH2-PEG3-C2-NH-Boc 在生命科学相关研究中具有广泛的应用。

Ph-Bis(C1-N-(C2-NH-Boc)2) is a versatile alkyl chain-derived linker employed in the synthesis of PROTACs[1].

Boc-NH-PEG15-NH2 is a PEG-based linker for PROTACs which joins two essential ligands, crucial for forming PROTAC molecules. This linker enables selective protein degradation by leveraging the ubiquitin-proteasome system within cells.

Biotin-PEG3-(CH2)3-NH2 TFA salt is a PEG-based linker for PROTACs which joins two essential ligands, crucial for forming PROTAC molecules. This linker enables selective protein degradation by leveraging the ubiquitin-proteasome system within cells.

Mal-NH2 TFA is a alkyl chain-based linker for PROTACs which joins two essential ligands, crucial for forming PROTAC molecules. This linker enables selective protein degradation by leveraging the ubiquitin-proteasome system within cells.

Thalidomide-NH-C6-NH2 is a synthetic conjugate compound designed as an E3 ligase ligand-linker. It consists of a Thalidomide-based cereblon ligand linked to a specific linker utilized in PROTAC technology[1].

Thalidomide-NH-C9-NH2 hydrochloride 是一种Thalidomide衍生的cereblon配体，能够募集CRBN蛋白。该化合物可利用linker与特定靶蛋白配体相连，用于构建PROTAC分子，如THAL-SNS-032。

Thalidomide-5-NH-PEG2-NH2 hydrochloride，为基于Thalidomide的cereblon配体，能够募集CRBN蛋白。通过linker与靶蛋白配体相连，用于形成PROTAC分子，如THAL-SNS-032。

Cereblon Ligand -Linker Conjugates 2 TFA 是一种 E3 连接酶配体- linker 偶联物，包含基于 Thalidomide 的 cereblon 配体和 linker。

Thalidomide-O-amido-PEG1-(C1-PEG)2-C2-NH2 is a synthesized conjugate compound known as an E3 ligase ligand-linker. It incorporates a cereblon ligand based on Thalidomide and a 3-unit PEG linker. This compound is specifically designed for use in PROTAC technology applications.

Pomalidomide-PEG3-C2-NH2 TFA is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 3-unit PEG linker used in PROTAC technology.

NH2-PEG4-Glu(OH)-NH-m-PEG24 is a PEG-based PROTAC linker suitable for PROTAC synthesis[1].

Thalidomide-5-NH-PEG3-NH2 hydrochloride 是Thalidomide衍生物，能够募集CRBN (cereblon) 蛋白的配体。该化合物利用linker与靶标蛋白配体进行连接，进而形成PROTAC分子，如THAL-SNS-032。

Functionalized cereblon ligand for PROTAC research and development; incorporates an E3 ligase ligand plus an alkylC5 linker with terminal amine ready for conjugation to a target protein ligand. Part of a range of functionalized tool molecules for PROTAC R&D. This product has been recently renamed. The previous name for this product was Pomalidomide - linker 4 PROTAC is a registered trademark of Arvinas Operations, Inc., and is used under license.

Thalidomide-NH-C8-NH2 hydrochloride is a synthetic compound, which functions as an E3 ligase ligand-linker conjugate. It consists of a cereblon ligand derived from Thalidomide, along with a linker commonly used in PROTAC technology.

Thalidomide-NH-C8-NH2 is a synthetic conjugate of an E3 ligase ligand-linker, which combines a cereblon ligand based on Thalidomide with a specific linker utilized in PROTAC technology.

Thalidomide-O-C6-NH2 TFA is a synthesized E3 ligase ligand-linker conjugate used in the PROTAC dTAG-13, a degrader of FKBP12F36V and BET[1].

Boc-NH-PEG2-C2-NH2 (PROTAC Linker 13) is a PEG-based linker utilized for the synthesis of PROTACs. This chemical compound plays a crucial role in connecting the targeted protein and the E3 ubiquitin ligase for selective protein degradation[1].

Boc-NH-PEG23-NH2 is a PEG-based linker for PROTACs which joins two essential ligands, crucial for forming PROTAC molecules. This linker enables selective protein degradation by leveraging the ubiquitin-proteasome system within cells.

Thalidomide-NH-C4-NH2 TFA (compound 29c) is a conjugate consisting of an E3 ligase ligand-linker, incorporating the Thalidomide-based cereblon ligand and a linker moiety. This compound, Thalidomide-NH-C4-NH2 TFA, is utilized as a component in PROTAC BRD2 BRD4 degrader-1, which is a highly potent and selective degrader targeting BET proteins BRD4 and BRD2[1].

Thalidomide-NH-CBP p300 ligand 2 (P-007) is a PROTAC-based compound designed to degrade CBP and p300, acting as a functional antagonist (WO2020173440).

Mal-PEG2-NH2 TFA is a PEG-based linker for PROTACs which joins two essential ligands, crucial for forming PROTAC molecules. This linker enables selective protein degradation by leveraging the ubiquitin-proteasome system within cells.

Thalidomide-O-amido-PEG1-(C1-PEG)2-C2-NH2 is a synthetic conjugate compound that combines a Thalidomide-based cereblon ligand and a linker, which is commonly utilized in PROTAC technology. This compound acts as a connector between the target protein and the E3 ligase, facilitating targeted protein degradation.

Mal-PEG4-Lys(TFA)-NH-m-PEG24 is a polyethylene glycol (PEG) derivative specifically designed as a PROTAC linker for the synthesis of proteolysis targeting chimeras (PROTACs) [1].

Fmoc-NH-PEG3-C2-NH2 is a PEG-based linker for PROTACs which joins two essential ligands, crucial for forming PROTAC molecules. This linker enables selective protein degradation by leveraging the ubiquitin-proteasome system within cells.

(S,R,S)-AHPC-C3-NH2 TFA (VH032-C3-NH2 TFA) is a synthesized E3 ligase ligand-linker conjugate that incorporates the VH032 based VHL ligand and a linker used in PROTAC technology. (S,R,S)-AHPC-C3-NH2 can be used in the synthesis of a series of PROTACs, suc

NH2-PEG5-C2-NH-Boc (PROTAC Linker 17) is a PEG-based compound utilized as a linker in the synthesis of PROTACs[1].

Thalidomide-NH-C6-NH2 TFA is a synthetic conjugate compound that combines a cereblon ligand based on Thalidomide with a linker used in PROTAC technology, functioning as an E3 ligase ligand-linker conjugate[1].

Thalidomide-NH-(CH2)2-NH2 TFA 是一种烷基修饰的 Thalidomide，用作 Cereblon 配体以招募 CRBN 蛋白。它是在以 CRBN 为基础设计的 PROTAC 分子合成中的关键中间体，并用于合成针对 SHP2 蛋白的 PROTAC 小分子。

Fmoc-NH-PEG5-C2-NH2 is a PEG-based linker for PROTACs which joins two essential ligands, crucial for forming PROTAC molecules. This linker enables selective protein degradation by leveraging the ubiquitin-proteasome system within cells.

Mal-PEG4-C2-NH2 TFA is a PEG-based linker for PROTACs which joins two essential ligands, crucial for forming PROTAC molecules. This linker enables selective protein degradation by leveraging the ubiquitin-proteasome system within cells.